- Therapeutic decisions in cancer patients with concomitant rheumatoid arthritis need to consider risk-benefit ratios of different therapies with respect to cancer prognosis, quality of life, and patient preferences.
- Some antirrheumatic biologic therapies may impair immune-mediated antitumor responses and therefore require careful consideration when their use is contemplated in patients with active cancer.
- For patients with a history of cancer and no recurrences, antirrheumatic therapy appears to be safe, with no evidence that it increases recurrence rates.
- Data are limited on the use of immune checkpoint inhibitors in cancer patients with pre-existing rheumatoid arthritis; in about half of the cases reported, patients had a disease flare.
- Comanagement by oncologists and rheumatologists can reduce the risk of complications and improve symptom control and quality of life in patients with active arthritis.